BiotechTube

RP2 + Ipilimumab + Nivolumab

Phase 2/3Recruiting
0 watching 0 views this week⚡ Active
57
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Uveal Melanoma

Conditions

Metastatic Uveal Melanoma

Trial Timeline

Dec 17, 2024 → Oct 1, 2031

NCT ID
NCT06581406

About RP2 + Ipilimumab + Nivolumab

RP2 + Ipilimumab + Nivolumab is a phase 2/3 stage product being developed by Replimune for Metastatic Uveal Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06581406. Target conditions include Metastatic Uveal Melanoma.

Hype Score Breakdown

Clinical
22
Activity
15
Company
2
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT06581406Phase 2/3Recruiting

Competing Products

20 competing products in Metastatic Uveal Melanoma

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
AbemaciclibEli LillyPre-clinical
23
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
SYNB1891 + AtezolizumabSynlogicPhase 1
25
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
77
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
41
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Induction therapyChugai PharmaceuticalPhase 2
52
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
52
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
52
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
GC33Chugai PharmaceuticalPhase 1
33
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
DS9051bDaiichi SankyoPhase 1
33

Other Products from Replimune

Vusolimogene Oderparepvec + Nivolumab + Nivolumab + Relatlimab + Pembrolizumab + Single-agent chemotherapyPhase 3
69
RP2 + Bevacizumab + Atezolizumab + Durvalumab + RP2 MonotherapyPhase 2
44
RP2 + Pegfilgrastim + FilgrastimPhase 2
44
Vusolimogene Oderparepvec (VO) + PembrolizumabPhase 2
44
RP2 InjectionPhase 2
44